

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

1. (Original) An iRNA capable of selectively inhibiting the expression of an ANT isoform, characterized in that said iRNA is an RNA duplex, one of the strands being highly homologous to a fragment of the mRNA encoding said ANT isoform.
2. (Original) The iRNA as claimed in claim 1, characterized in that it is an siRNA of 18 to 25 nucleotides, more particularly of 21 nucleotides.
3. (Original) The iRNA as claimed in claim 2, characterized in that it has the sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3.
4. (Currently Amended) A construct containing at least one iRNA as claimed in claim 1 ~~any one of claims 1 to 3~~, or DNA sequences encoding each of the strands of these iRNAs.
5. (Original) The construct as claimed in claim 4, characterized in that the iRNA is associated with a vector that facilitates its administration, its passage across membranes, tissues or biological integuments, in particular cytoplasmic membranes, mitochondrial membranes, nuclear membranes, skin, mucous membranes, endothelial walls, the blood-brain barrier, and also its bioavailability, its stability and its pharmacodistribution, such as a peptide, a liposome, nanoparticles (nanospheres, nanotubes), or a non-natural oligomer such as urea oligomers.
6. (Original) The construct as claimed in claim 4, characterized in that the

vectors are vectors for transferring nucleic acids, such as retroviruses, transposons, adenoviruses or plasmids.

7. (Currently Amended) A pharmaceutical composition characterized in that it contains an effective amount of at least one iRNA as claimed in claim 1 ~~any one of claims 1 to 3~~, or a construct containing at least one of said iRNA or DNA sequences encoding each of the strands of these iRNAs ~~as claimed in any one of claims 4 to 6~~, in combination with a pharmaceutically acceptable vehicle.

8. (Original) The pharmaceutical composition as claimed in claim 7, characterized in that it is in injectable form, or in a form that can be administered orally, parenterally, rectally or topically.

9. (Currently Amended) The iRNA as claimed in claim 1 ~~any one of claims 1 to 3~~, or a the construct containing at least one of said iRNA or DNA sequences encoding each of the strands of these iRNAs ~~as claimed in any one of claims 1 to 6~~, or a the pharmaceutical composition containing an effective amount of at least one of the iRNA ~~as claimed in claim 7 or 8~~, characterized in that it has the ability to regulate (to induce or to inhibit) mitochondrial membrane permeabilization and cell death of apoptotic, necrotic and autophagic type, and related mechanisms.